SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 6, 2012--
Celgene Corporation (NASDAQ: CELG) today announced its intention
to offer, subject to market and other conditions, senior unsecured notes
under a shelf registration statement on Form S-3 on file with the
Securities and Exchange Commission. The interest rate, the maturity
dates and other key terms of the offering are to be determined at the
time of pricing.
Celgene expects to use the net proceeds from the offering for general
corporate purposes, which may include, without limitation, further
development of Celgene’s clinical and pre-clinical programs, capital
expenditures, general corporate development activities and meeting
working capital needs.
BofA Merrill Lynch, J.P. Morgan and Morgan Stanley are acting as joint
book-running managers. A copy of the preliminary prospectus supplement
and the accompanying base prospectus, which is filed as part of
Celgene’s effective shelf registration statement on Form S-3 (File No.
333-169731), may be obtained from any of the joint book-running managers
by calling BofA Merrill Lynch toll-free at: 1-800-294-1322, J.P. Morgan
collect at 1-212-834-4533 or Morgan Stanley toll-free at 1-866-718-1649.
An electronic copy of the preliminary prospectus supplement and the
accompanying base prospectus may also be obtained at no charge at the
Securities and Exchange Commission’s website at www.sec.gov.
The notes are being offered pursuant to an effective registration
statement on Form S-3 (File No. 333-169731) that Celgene previously
filed with the Securities and Exchange Commission. This press release
does not constitute an offer to sell or a solicitation of an offer to
buy the notes described herein, nor shall there be any sale of these
notes in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
laws of such jurisdiction. The offering of the notes will be made only
by means of a prospectus supplement and the accompanying base prospectus.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of novel therapies for the
treatment of cancer and inflammatory diseases through gene and protein
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
Source: Celgene Corporation
Jacqualyn A. Fouse, Ph.D, 908-673-9956
Chief Financial Officer
Patrick E. Flanigan III,
VP, Investor Relations